Prevymis (letermovir) - Merck (MSD)
Letermovir: an enticing new CMV prophylaxis option with growing evidence in heart and lung transplantation. (PubMed, J Heart Lung Transplant) - Sep 28, 2025 - No abstract available 
Journal • Cytomegalovirus Infection • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/41015400
 
Bradley J Gardiner; Jack L Skeggs
 
Sep 28, 2025
 
Prev Next